BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 18803555)

  • 21. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overall asthma control: the relationship between current control and future risk.
    Bateman ED; Reddel HK; Eriksson G; Peterson S; Ostlund O; Sears MR; Jenkins C; Humbert M; Buhl R; Harrison TW; Quirce S; O'Byrne PM
    J Allergy Clin Immunol; 2010 Mar; 125(3):600-8, 608.e1-608.e6. PubMed ID: 20153029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
    Nannini L; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budesonide/formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted 'real life' setting.
    Søes-Petersen U; Kava T; Dahle R; Lei Y; Dam N
    Clin Respir J; 2011 Jul; 5(3):173-82. PubMed ID: 21679353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.
    Wickstrøm J; Dam N; Malmberg I; Hansen BB; Lange P
    Clin Respir J; 2009 Jul; 3(3):169-80. PubMed ID: 20298400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?
    Aubier M; Haughney J; Selroos O; van Schayck OC; Ekström T; Ostinelli J; Buhl R
    Ther Adv Respir Dis; 2011 Oct; 5(5):289-98. PubMed ID: 21586508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
    Busse WW; Shah SR; Somerville L; Parasuraman B; Martin P; Goldman M
    J Allergy Clin Immunol; 2008 Jun; 121(6):1407-14, 1414.e1-6. PubMed ID: 18455221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients.
    Price D; Small I; Haughney J; Ryan D; Gruffydd-Jones K; Lavorini F; Harris T; Burden A; Brockman J; King C; Papi A
    Prim Care Respir J; 2013 Dec; 22(4):439-48. PubMed ID: 24186700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
    Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
    Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.
    Lasserson TJ; Cates CJ; Ferrara G; Casali L
    Cochrane Database Syst Rev; 2008 Jul; (3):CD004106. PubMed ID: 18646100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE; Hagiwara M; Stanford RH; Stempel DA
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination.
    Angus R; Reagon R; Cheesbrough A
    Int J Clin Pract; 2005 Feb; 59(2):156-62. PubMed ID: 15854190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Nannini LJ; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006829. PubMed ID: 22972099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma.
    Ankerst J
    J Asthma; 2005 Nov; 42(9):715-24. PubMed ID: 16316864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pitfalls associated with the therapeutic reference pricing practice of asthma medication.
    Kalo Z; Abonyi-Toth Z; Bartfai Z; Voko Z
    BMC Pulm Med; 2012 Jul; 12():35. PubMed ID: 22818402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids.
    Chan J; Hui RL; Spence MM
    J Manag Care Pharm; 2007; 13(1):21-7. PubMed ID: 17269833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.